OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

Post-LOE

olanzapine and fluoxetine

Teva

ANDAORALCAPSULE

Approved

Mar 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE (olanzapine and fluoxetine) by Teva is indications, is unclear. Approved for depression, depression. First approved in 2013.

Drug data last refreshed Yesterday

Mechanism of Action

indications, is unclear. However, the combined effect of olanzapine and fluoxetine at the monoaminergic neural systems (serotonin, norepinephrine, and dopamine) could be responsible for the pharmacological effect.

Pharmacologic Class:

Atypical Antipsychotic

Indications (1)

depression

Clinical Trials (1)

NCT01687478Phase 3Terminated

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

Started Sep 2012

176 enrolled

Treatment Resistant Depression

Company

Worked on OLANZAPINE AND FLUOXETINE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.